NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2023.
PMV Pharmaceuticals reported a net loss of $19.1 million for the quarter ended March 31, 2023, compared to a net loss of $18.4 million for the quarter ended March 31, 2022. The company ended the quarter with $229.4 million in cash, cash equivalents, and marketable securities.
- Continued progress in the PYNNACLE study of PC14586, with the next update expected in 2H 2023.
- Enrollment commenced in the combination arm of the PYNNACLE study with PC14586 and KEYTRUDA.
- Ended the first quarter with $229.4 million in cash, cash equivalents, and marketable securities.
- Net cash used in operations was $15.0 million for the three months ended March 31, 2023.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
The company's future plans include expectations regarding timing for its Phase 1 and regulatory update for the PYNNACLE study and its Phase 1/2 combination trial of PC14586 and KEYTRUDA, as well as expectations regarding success of its current clinical trial for PC14586 and any future commercialization plans for the product candidate.
Tailwinds
- Ongoing progress in the PYNNACLE study of PC14586.
- Enrollment commenced in the combination arm of the PYNNACLE study with PC14586 and KEYTRUDA.
- The Company’s future plans or expectations for PC14586
- Expectations regarding timing for its Phase 1 and regulatory update for the PYNNACLE study
- Expectations regarding success of its current clinical trial for PC14586 and any future commercialization plans for the product candidate.
Headwinds
- The success, cost, and timing of the Company’s product candidate development activities and planned clinical trials
- The Company’s ability to execute on its strategy and operate as an early clinical stage company
- The potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results
- The Company’s ability to fund operations
- The impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro